ÅǸ޴º
¹øÈ£ | ±¸ºÐ | Á¦¸ñ |
---|---|---|
13 | (±¹¿Ü)SCIE | An investigation of the metabolism and excretion of KD101 and its inter-individual differences: a microtracing mass balance study in humans |
12 | (±¹¿Ü)SCIE | Increasing Prevalence and Mortality of Asthma With Age in Korea, 2002. 2015: A Nationwide, Population-Based Study |
11 | (±¹¿Ü)SCIE | Trabecular Bone Score Is More Sensitive to Asthma Severity and Glucocorticoid Treatment Than Bone Mineral Density in Asthmatics |
10 | (±¹³»)SCOPUS | Bioequivalence of the pharmacokinetics between tofacitinib aspartate and tofacitinib citrate in healthy subjects |
9 | (±¹¿Ü)SCIE | Development of a Pharmacokinetic Model Describing Neonatal Fc Receptor-Mediated Recycling of HL2351, a Novel Hybrid Fc-Fused Interleukin-1 Receptor Antagonist, to Optimize Dosage Regimen |
8 | (±¹¿Ü)SCIE | An investigation of the metabolism and excretion of KD101 and its inter-individual differences: a microtracing mass balance study in humans |
7 | (±¹¿Ü)SCIE | Increasing Prevalence and Mortality of Asthma With Age in Korea, 2002?2015: A Nationwide, Population-Based Study |
6 | (±¹¿Ü)SCIE | Trabecular Bone Score Is More Sensitive to Asthma Severity and Glucocorticoid Treatment Than Bone Mineral Density in Asthmatics |
5 | (±¹¿Ü)SCI | An investigation of the metabolism and excretion of KD101 and its inter-individual differences: a microtracing mass balance study in humans |
4 | (±¹¿Ü)SCIE | Exposure-response and Clinical Outcome Modeling of Inhaled Budesonide/Formoterol Combination in Asthma Patients |
Copyright ¨Ï chamc, All rights reserved.